

DAFTAR PUSTAKA

- Assistance Publique – Hopitaux de Paris. 2020. Cohort multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients – sarilumab trial – CORIMUNO-19- SARI (CORIMUNO-SARI). (<https://clinicaltrials.gov/ct2/show/NCT04324073?term=sarilumab&draw=3&rank=2>. Diakses 11 Agustus 2020)
- Assistance Publique – Hopitaux de Paris. 2020. Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO (CORIMUNO-VIRO). (<https://clinicaltrials.gov/ct2/show/NCT04341870?term=sarilumab&cond=SARS-CoV+2&draw=2&rank=1> Diakses 11 Agustus 2020, 2020)
- Benfield T. 2020. Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia (CCAP). (<https://clinicaltrials.gov/ct2/show/NCT04345289?cond=COVID&intr=Baricitinib&draw=2&rank=4> Diakses 11 Agustus 2020)
- Branch-Elliman W. 2020. Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design. (<https://clinicaltrials.gov/ct2/show/NCT04359901?cond=COVID&intr=Sarilumab&draw=2&rank=1>. Diakses 11 Agustus 2020.
- Burmester, Gerd R et al. 2017. “Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.” *Annals of the rheumatic diseases* vol. 76,5 (2017): 840-847. doi:10.1136/annrheumdis-2016-210310
- Benucci, et al, 2020, COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients, *J Med Virol*, DOI: 10.1002/jmv.26062
- Christina C. Price, et all, 2020, Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients Survival and Clinical Outcomes, *CHEST-20-2148*.

- Della-Torre, Emanuel et al. 2020 : "Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study." *Annals of the rheumatic diseases* vol. 79,10 1277-1285. doi:10.1136/annrheumdis-2020-218122
- Di Giambenedetto, et al, 2020, SARS-CoV-2 infection in a highly-experienced person living with HIV, *Wolters Kluwer Health*, DOI: 10.1097/QAD.0000000000002572
- David Moher,et.all, 2015, Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
- Drugbank. Diakses 20 Juni 2020
<https://www.drugbank.ca/drugs/DB11767>
- Garcia de Vicuna Pinedo M. 2020. Efficacy of subcutaneous sarilumab in hospitalised patients with moderatesevere COVID-19 infection (SARCOVID) (<https://clinicaltrials.gov/ct2/show/NCT04357808?cond=COVID&intr=Sarilumab&draw=2&rank=2>. Diakses 11 Agustus 2020)
- Genovese, Mark C et al. 2015. "Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study." *Arthritis & rheumatology (Hoboken, N.J.)* vol. 67,6: 1424-37. doi:10.1002/art.39093
- Gopalakrishnan, S, and P Ganeshkumar. 2013. "Systematic Reviews and Meta-analysis: Understanding the Best Evidence in Primary Healthcare." *Journal of family medicine and primary care* vol. 2,1: 9-14. doi:10.4103/2249-4863.109934.
- Gremese, Elisa et al. 2020. "Sarilumab use in severe SARS-CoV-2 pneumonia." *EClinicalMedicine*, 100553. doi:10.1016/j.eclinm.2020.100553
- Henriksen M. Anti-il6 treatment of serious COVID-19 disease With threatening respiratory failure (TOCIVID). (<https://clinicaltrials.gov/ct2/show/NCT04322773?cond=Coronavir us&intr=sarilumab&draw=2&rank=3>. Diakses 11 Agustus 2020.)
- Elsevier.Sarilumab drug monograph.
https://www.elsevier.com/_data/assets/pdf_file/0010/1000243/Sarilumab-Drug-Monograph_18MAY2020.pdf

- Ibadurrahman, Muhammad Alief. 2020. "Coronavirus Asal Usul, Penyebaran, Dampak, dan Metode Pencegahan Efektif Pandemi Covid-19." Altman, D.G. 1991. Sample Size. In Altman, D.G., Ed., Practical Statistics for Medical Research, Chapman & Hall, London, 455-460.
- Joannabriggs.org. 2017. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews. https://joannabriggs.org/sites/default/files/201905/JBI_RCTs_Appraisal_tool2017_0.pdf
- J.-M. Michot , L. Albiges, et.all, 2020, Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report, *Elsevier Ltd.* <https://doi.org/10.1016/j.annonc.2020.03.300>
- Jared Radbel, 2020, Use of Tocilizumab for COVID-19- Induced Cytokine Release Syndrome A Cautionary Case Report, *Elsevier* <https://doi.org/10.1016/j.chest.2020.04.024>
- Jiancheng Zhang, et.al, 2020. "Current status of potential therapeutic candidates for the COVID-19 crisis,Brain, Behavior, and Immunity", Volume 87, , Pages 59-73, ISSN 0889-1591, <https://doi.org/10.1016/j.bbi.2020.04.046>.
<http://www.sciencedirect.com/science/article/pii/S0889159120305894>
- Jiang, Fang et al. 2020. "Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)." *Journal of general internal medicine* vol. 35,5: 1545-1549. doi:10.1007/s11606-020-05762-w
- Kato, S., & Kurzrock, R. 2020. Repurposing Interleukin-6 Inhibitors to Combat COVID-19. *Journal of Immunotherapy and Precision Oncology*, 3(2), 52-55. <http://dx.doi.org/10.36401/jipo-20-11>
Retrieved from <https://escholarship.org/uc/item/5ft476n6>
- Li, Heng et al. 2020. "Coronavirus disease 2019 (COVID-19): current status and future perspectives." *International journal of antimicrobial agents* vol. 55,5: 105951. doi:10.1016/j.ijantimicag.2020.105951
- Maimonides Biomedical Research Institute of Cordoba. 2020. Clinical trial of sarilumab in adults With COVID-19 (SARICOR). (<https://clinicaltrials.gov/ct2/show/NCT04357860?cond=COVID&intr=Sarilumab&draw=2&rank=5>. Diakses 11 Agustus 2020)

MIMS home, Concise Prescribing Info. Diakses tanggal Diakses 6 Juni 2020. <https://www.mims.com//malaysia/drug/info/sarilumab?mtype=generic>

McHugh, Mary. (2012). Interrater reliability: The kappa statistic. *Biochemia medica : časopis Hrvatskoga društva medicinskih biokemičara / HDMB*. 22. 276-82. 10.11613/BM.2012.031.

Ouzzani, Mourad, et al. 2016 "Rayyan-a web and mobile app for systematic reviews. *Systematic Reviews*, 5, 210."

Perhimpunan Dokter Paru Indonesia (PDPI), 2020, *Pneumonia Covid-19 Diagnosis & Penatalaksanaan Di Indonesia*. Jakarta.ISBN: 978-623-92964-0-7

Piper, Brian J et al. 2019. "A Quantitative and Narrative Evaluation of Goodman and Gilman's Pharmacological Basis of Therapeutics." *Pharmacy (Basel, Switzerland)* vol. 8,1 1. 20 Dec., doi:10.3390/pharmacy8010001

Regeneron Pharmaceuticals. 2020. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19. (<https://clinicaltrials.gov/ct2/show/study/NCT04315298?term=sarilumab&draw=2>. Diakses 11 Agustus 2020)

Rothan, Hussin A, and Siddappa N Byrareddy. (2020). "The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak." *Journal of autoimmunity* vol. 109: 102433. doi:10.1016/j.jaut.2020.102433

Salvatore Crisafulli, et.all, 2020, Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks, *BioDrugs*, <https://doi.org/10.1007/s40259-020-00430-1>

Sanofi. Sarilumab COVID-19. (<https://clinicaltrials.gov/ct2/show/NCT04327388?cond=Coronavirus&intr=sarilumab&draw=2&rank=2>. Diakses 11 Agustus 2020).

Sanofi-and-Regeneron, 2020, Diakses 16 Maret 2020. <http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19>

Satish Tadepalli,et all, 2020, The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series, *Cureus* DOI: 10.7759/cureus.8631,

- Senanayake, Suranga L. 2020 "Drug repurposing strategies for COVID-19." *Future Drug Discovery* vol. 0,0): fdd-2020-0010. doi:10.4155/fdd-2020-0010
- Senger, Mario. 2020. COVID-19: drug repurposing and new insights for drug discovery. 10.1590/0074-02760200254.
- Shengyu Zhang, et.al, 2020, Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia, *Clinical Drug Investigation* (<https://doi.org/10.1007/s40261-020-00917-3>)
- Sim,J.,Wright, CC. 2005. The Kappa Statistic in Reliability Studies: Use, Interpretation dan Sample Size Requirements. *Physical Therapy*, Vol.85, Issue 3, 1 Maret 2005. Halaman 257-268: <https://doi.org/10.1093/ptj/85.3.257>
- Siswanto. 2010. "Systematic review sebagai metode penelitian untuk mensintesis hasil-hasil penelitian (sebuah pengantar)." *Buletin Penelitian Sistem Kesehatan* 13.4: 21312.
- Snyder, Hannah. 2019. "Literature review as a research methodology: An overview and guidelines." *Journal of Business Research* 104: 333-339.
- Stefano Rusconi, ASST Fatebenefratelli Sacco, Study on the Use of Sarilumab in Patients With COVID-19 Infection . (<https://clinicaltrials.gov/ct2/show/NCT04386239>. Diakses 11 Agustus 2020).
- Tobaiqy, M. et al. 2020. "Therapeutic management of patients with COVID-19: a systematic review." *Infection Prevention in Practice* vol. 2,3 : 100061. doi:10.1016/j.infpip.2020.100061
-
- Vellas, C et al. 2020. "COVID-19, Virology and Geroscience: A Perspective." *The journal of nutrition, health & aging* vol. 24,7: 685-691. doi:10.1007/s12603-020-1416-2
- Vellingiri, Balachandar, et al. 2020. "COVID-19: A promising cure for the global panic." *Science of The Total Environment* : 138277.
- World Health Organization, 2020, Data Collection. Diakses 6 Juni 2020. <https://covid19.who.int/>

LAMPIRAN

1. Tabel hasil telaah kritis artikel 1

COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients

JBI Critical Appraisal Checklist for Case Series

Reviewer : SS, MAB

Date : 05 Agustus 2020

Author : Maurizio Benucci MD, et.al

Year : 2020

		YES	NO	UNCLEAR	NA
NO					
1	Were there clear criteria for inclusion in the case series?		√		
2	Was the condition measured in a standard, reliable way for all participants included in the case series?	√			
3	Were valid methods used for identification of the condition for all participants included in the case series?			√	
4	Did the case series have consecutive inclusion of participants?			√	
5	Did the case series have complete inclusion of participants?		√		
6	Was there clear reporting of the demographics of the participants in the study?	√			
7	Was there clear reporting of clinical information of the participants?	√			
8	Were the outcomes or follow up results of cases clearly reported?	√			

9	Was there clear reporting of the presenting site(s)/clinic(s) demographic information?		√		
10	Was statistical analysis appropriate?				√

2. Tabel hasil telaah kritis artikel 2

SARS-CoV-2 infection in a highly-experienced person living with HIV

JBIC Critical Appraisal Checklist for Case Reports

Reviewer : SS, MAB

Date : 05 Agustus 2020

Author : Di Giambenedetto S, et al

Year : 2020

		YES	NO	UNCLEAR	NA
NO					
1	Were patient's demographic characteristics clearly described?	√			
2	Was the patient's history clearly described and presented as a timeline?	√			
3	Was the current clinical condition of the patient on presentation clearly described?	√			
4	Were diagnostic tests or assessment methods and the results clearly described?	√			
5	Was the intervention(s) or treatment procedure(s) clearly described?		√		
6	Was the post-intervention clinical condition clearly described?	√			
7	Were adverse events (harms) or unanticipated events identified and described?	√			
8	Does the case report provide takeaway lessons?	√			

3. Perhitungan Persetujuan Kajian Sistematis

		Pengamat 1/ reviewer 1		
		Ya	Tidak	Jumlah
Pengamat 2/ reviewer 2	Ya	a	b	a + b
	Tidak	c	d	c + d
	Jumlah	a + c	b + d	a + b + c + d = n

Ket:

$$\text{Persetujuan} = (a + d)/n$$

$$\text{Nilai Persetujuan} = \text{Pox}100\%$$

$$\text{Cohen's Kappa} = (P_o - P_e) / (1 - P_e)$$

$$P_o = (a + d)/n$$

$$P_e = [(a + c)(a + b)/n + (b + d)(c + d)/n] / n$$

Kategori nilai *Cohen's Kappa* :

$$0.00 \leq k \leq 0.20 = \text{Rendah}$$

$$0.21 \leq k \leq 0.40 = \text{Lumayan}$$

$$0.41 \leq k \leq 0.60 = \text{Cukup}$$

$$0.61 \leq k \leq 0.80 = \text{Baik}$$

$$0.81 \leq k \leq 1.00 = \text{Sangat baik}$$

1). Skrining Fase I (*TIAB screening*)

		Pengamat 1/ reviewer 1		
		include	exclude	Jumlah
Pengamat 2/ reviewer 2	include	12	7	19
	exclude	0	54	54
	Jumlah	12	61	73

$$Po = 0,904$$

$$Pe = 0,660$$

$$\text{Nilai Persetujuan} = Pox100\%$$

$$= 90,4\%$$

$$Cohen's\ Kappa\ (Po-Pe)/(1-Pe) = 0,72$$

2). Skrining Fase II (*Full Text screening*)

		Pengamat 1/ reviewer 1		
		include	exclude	Jumlah
Pengamat 3/ reviewer 3	include	2	0	2
	exclude	0	10	10
	Jumlah	2	10	12

$$Po = 1,00$$

$$Pe = 0,667$$

$$\text{Nilai Persetujuan} = Pox100\%$$

$$= 100\%$$

$$Cohen's\ Kappa = (Po-Pe)/(1-Pe) = 1,00$$

